Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.1100 (-0.71%) ($11.1100 - $11.1100) on Mon. Apr. 10, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.34% (three month average) | RSI | 38 | Latest Price | $11.1100(-0.71%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.2% a day on average for past five trading days. | Weekly Trend | FOLD declines -0.5% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(60%) IBB(57%) IWM(44%) IWO(44%) IWN(42%) | Factors Impacting FOLD price | FOLD will decline at least -1.17% in a week (0% probabilities). TBT(-22%) VXX(-15%) UUP(-12%) EDOC(-8%) VIXM(-7%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.17% (StdDev 2.34%) | Hourly BBV | 0.1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $11.2 | 5 Day Moving Average | $11.1(0.09%) | 10 Day Moving Average | $11.09(0.18%) | 20 Day Moving Average | $11.2(-0.8%) | To recent high | -18.6% | To recent low | 1.7% | Market Cap | $2.869b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |